Allison Barnes, NP
Adult Health · Griffin, GANPI 1407247877
Payments from drug & device makers
Across 131 payments — averaging $16.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$378
- Pfizer$242
- Lilly USA, LLC$193
- Novo Nordisk$176
- Astellas Pharma US Inc$168
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$115
- plus $928 from 24 others
What the payments were for
- Food & beverage$2,199100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 24 | $378 |
| Pfizer | 14 | $242 |
| Lilly USA, LLC | 12 | $193 |
| Novo Nordisk | 9 | $176 |
| Astellas Pharma US Inc | 11 | $168 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $115 |
| AstraZeneca | 8 | $114 |
| Boston Scientific | 4 | $96 |
| Medtronic | 5 | $78 |
| Boehringer Ingelheim | 3 | $64 |
| Dexcom, Inc. | 4 | $60 |
| Avanir Pharmaceuticals, Inc. | 3 | $57 |
| Johnson & Johnson | 4 | $55 |
| AbbVie | 3 | $52 |
| GSK | 3 | $46 |
| Novartis | 3 | $45 |
| Ultragenyx Pharmaceutical Inc. | 1 | $28 |
| Smith+Nephew | 2 | $28 |
| Vapotherm Inc | 1 | $26 |
| Corcept Therapeutics | 1 | $22 |
| Bayer | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Merck | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Exact Sciences | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $12 |
| Clarus Therapeutics Inc. | 1 | $12 |
How this compares
$2,199 in reported general payments places this provider in the 75th percentile of 577 adult health providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 108 | $118,168 |
| OzempicSemaglutide | 85 | $93,665 |
| EliquisApixaban | 70 | $65,749 |
| JanuviaSitagliptin Phosphate | 45 | $42,536 |
| ProliaDenosumab | 20 | $35,006 |
| JardianceEmpagliflozin | 34 | $30,330 |
| TrulicityDulaglutide | 20 | $28,228 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $24,654 |
| XareltoRivaroxaban | 31 | $22,092 |
| MyrbetriqMirabegron | 29 | $17,456 |
| Spiriva RespimatTiotropium Bromide | 27 | $16,994 |
| FarxigaDapagliflozin Propanediol | 12 | $14,926 |
| EntrestoSacubitril/Valsartan | 16 | $14,158 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 14 | $10,761 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 52 | $8,788 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $193 | $146,395128 claims |
| Novo NordiskOzempic | $176 | $93,66585 claims |
| PfizerEliquis | $242 | $65,74970 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $64 | $47,32561 claims |
| MerckJanuvia | $17 | $42,53645 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Shingrix | $46 | $39,52466 claims |
| AmgenProlia | $378 | $35,00620 claims |
| Johnson & JohnsonXarelto | $55 | $22,09231 claims |
| AstraZenecaFarxiga, Symbicort | $114 | $21,78637 claims |
| Astellas Pharma US IncMyrbetriq | $168 | $17,45629 claims |
| NovartisEntresto | $45 | $14,15816 claims |
| AbbVieSynthroid | $52 | $4,48737 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 577 adult health providers in Georgia.
Other adult health in Griffin
- Patricia KeeganAtlanta$224K
- Diane WirthAtlanta$132K
- Barbara WeberAtlanta$74K
- Terry HackworthAtlanta$49K
- Jenny DicksonCumming$39K
- Rachel NejemLawrenceville$31K
- Melissa BaughcumAthens$23K
- Kristine AdamsMarietta$21K
- Jenina LagascaAtlanta$17K
- Jennifer SheldonMacon$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.